Method for producing alpha-type crystals of reduced glutathione and method for preserving said crystals
By coexisting specific crystal modifiers with reduced glutathione during crystallization and storage, the production of high-quality and productive α-form crystals is achieved by preventing the transition to β-form crystals.
Patent Information
- Application Number
- JP2021021715
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2015-06-05
- Filing Date
- 2021-02-15
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2036-06-03
AI Technical Summary
Existing methods struggle to efficiently and stably produce α-form crystals of reduced glutathione, which are superior in quality and productivity, due to the generation of β-form crystals, and there is a lack of effective crystal modifiers for peptides like reduced glutathione.
The use of specific crystal modifiers such as aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, and dipeptides is introduced to coexist with reduced glutathione during crystallization and storage, suppressing the transition to β-form crystals.
This approach allows for the efficient and stable production of α-form crystals by inhibiting the generation and transition to β-form crystals, maintaining high solubility and processability.
Smart Images

Figure 0007577557000004 
Figure 0007577557000001 
Figure 0007577557000002
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing α-type crystals of reduced glutathione and a method for preserving the crystals. [Background technology]
[0002] Reduced glutathione is a tripeptide composed of three types of amino acids (glutamic acid, cysteine, and glycine), and has been used as a raw material for medicines and health foods as a material with antioxidant and detoxifying properties. In recent years, it is expected to be used in a wide range of other markets, including beverages and cosmetics.
[0003] Reduced glutathione crystals have two types of crystal polymorphism, α-type crystals and β-type crystals (Non-Patent Document 1). The solubility of unstable α-type crystals and stable β-type crystals is significantly different, with the saturated solubility at 10°C being 89 g / L for α-type crystals and 30 g / L for β-type crystals (Figure 1). Therefore, β-type crystals, which have low solubility, are difficult to process as raw materials and are difficult to handle. Furthermore, while α-type crystals are columnar and tend to grow large, small needle-shaped β-type crystals are poorly separable from the mother liquor, and are therefore inferior to α-type crystals in terms of both quality and productivity.
[0004] In addition, in a crystal slurry prepared by adding α-type crystals to a saturated solution of reduced glutathione α-type crystals and in a supersaturated solution of reduced glutathione, stable β-type crystals are easily generated, which significantly hinders efficient production of α-type crystals, which are a desirable crystal form. In such a situation, there has been a strong demand for the development of a method for suppressing the generation of β-type crystals and selectively crystallizing α-type crystals in a supersaturated solution of reduced glutathione.
[0005] On the other hand, the addition of a crystal habit modifier can be effective as a method for controlling the occurrence of crystal polymorphism of organic compounds such as amino acids (Patent Document 1, Non-Patent Document 2). However, in order for a crystal habit modifier to function effectively, it is subject to strict constraints, such as the chemical structure of the compound added as a crystal habit modifier having an extremely high similarity to the chemical structure of the target compound (Non-Patent Document 2) and furthermore, the molecular weight of the crystal habit modifier must be the same as or slightly smaller than the molecular weight of the target compound (Non-Patent Document 3). Due to these constraints, compounds with low structural similarity or compounds with molecular weights far removed from that of the target compound are generally excluded from the search for a crystal habit modifier.
[0006] There have been no known cases of controlling the occurrence of crystal polymorphism in peptides consisting of two or more amino acids, such as reduced glutathione, by adding a crystal habit modifier. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] JP 2010-59125 A [Non-patent literature]
[0008] [Non-Patent Document 1] Yamasaki, K. et al., Analytical Chemistry, 18(7), p874-878 (1969) [Non-Patent Document 2] Kuroda, K. et al., Yakugaku Zasshi, 99, p745-751 (1979) [Non-Patent Document 3] Momonaga, M. et al., Journal of Chemical Engineering, 18(5)p553-561 (1992) Summary of the Invention [Problem to be solved by the invention]
[0009] An object of the present invention is to provide a method for efficiently and stably producing and preserving α-type crystals of reduced glutathione that are excellent in both quality and productivity. [Means for solving the problem]
[0010] The present inventors conducted studies to solve the above problems, and discovered that the generation of β-type crystals and the transition to β-type crystals are significantly inhibited by causing a crystal habit modifier to coexist with an aqueous solution of reduced glutathione and α-type crystals, and that the generation of β-type crystals and the transition to β-type crystals are significantly suppressed by carrying out crystallization of α-type crystals of reduced glutathione in the presence of a crystal habit modifier, compared to the case in which no crystal habit modifier is added, and that α-type crystals can be produced efficiently and stably, thereby completing the present invention.
[0011] That is, the present invention is as follows. [1] A crystal habit modifier for suppressing the generation of β-type crystals of reduced glutathione and / or the transition from α-type crystals to β-type crystals of reduced glutathione, comprising at least one compound selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds, and dipeptides. [2] An α-type crystal of reduced glutathione containing the crystal habit modifier described in [1] above. [3] The crystals according to the above [2], wherein the content of the crystal habit modifier is 0.01 to 10% by weight based on the α-type crystals of reduced glutathione. [4] A method for producing α-type crystals of reduced glutathione, comprising the steps of adding the crystal habit modifier described in [1] above to an aqueous solution containing reduced glutathione, and crystallizing out α-type crystals of reduced glutathione. [5] The method according to the above [4], wherein the amount of the crystal habit modifier added is 0.01 to 10% by weight based on the reduced glutathione. [6] A method for preserving an aqueous solution of reduced glutathione, comprising the step of adding the crystal habit modifier described in [1] above to an aqueous solution of reduced glutathione. [7] The method according to [6] above, wherein the amount of the crystal habit modifier added is 0.01 to 10% by weight based on the reduced glutathione. [8] A method for preserving α-type crystals of reduced glutathione, comprising the step of adding the crystal habit modifier described in [1] above to α-type crystals of reduced glutathione. [9] The method according to the above [8], wherein the amount of the crystal habit modifier added is 0.01 to 10% by weight based on the reduced glutathione. Effect of the Invention
[0012] According to the present invention, by making a specific crystal habit modifier coexist during the production (crystallization) and storage of α-type crystals of reduced glutathione, the generation of β-type crystals and the transition from α-type crystals to β-type crystals are significantly suppressed, and α-type crystals of reduced glutathione can be produced efficiently and stably. [Brief description of the drawings]
[0013] [Figure 1] FIG. 1 is a diagram showing the solubility curves of α- and β-type crystals of reduced glutathione, with the vertical axis representing the solubility of each crystal in water at each temperature (g / L) and the horizontal axis representing temperature (°C). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] The present invention will be described in detail below. (definition)
[0015] As used herein, the term "reduced glutathione" refers to a tripeptide consisting of glutamic acid, cysteine, and glycine, as described above. The reduced glutathione used in the present invention may be one obtained by any production method, and examples thereof include those obtained by the method described in Japanese Patent Publication No. 57-016196.
[0016] The term "crystal habit modifier" generally refers to an additive that is added to change the crystal habit of a parent compound or to prevent the transition of polymorphism. In the present invention, however, the term "crystal habit modifier" particularly refers to an additive that suppresses the generation of β-type crystals of reduced glutathione and inhibits the transition from α-type crystals to β-type crystals of reduced glutathione during the production and storage of reduced glutathione α-type crystals. AdditivesThe crystal habit modifier used in the present invention includes aliphatic amino acids such as alanine and proline, sulfur-containing amino acids such as cysteine, aromatic amino acids such as phenylalanine and tryptophan, analogous compounds such as oxidized glutathione, and dipeptides such as alanylcysteine. Among them, at least one crystal habit modifier selected from the group consisting of L-cysteine, L-alanine, L-phenylalanine, L-tryptophan, D-proline, oxidized glutathione, and L-alanyl-L-cysteine is particularly preferred. The crystal habit modifier may be obtained by any production method, and examples thereof include those obtained by chemical synthesis, extraction, and fermentation.
[0017] In the present specification, the term "aliphatic amino acid" refers to hydrophobic amino acids that do not include aromatic amino acids. Examples of aliphatic amino acids include glycine, alanine, valine, leucine, isoleucine, proline, etc., and among these, L-alanine and D-proline are preferred.
[0018] As used herein, the term "sulfur-containing amino acid" refers to an amino acid that has a sulfur atom in its structure. Examples of sulfur-containing amino acids include cysteine, homocysteine, and methionine, with L-cysteine being preferred.
[0019] In the present specification, the term "aromatic amino acid" refers to a hydrophobic amino acid having an aromatic ring and an aromatic heterocycle. Examples of aromatic amino acids include phenylalanine, tryptophan, tyrosine, etc., and among these, L-phenylalanine and L-tryptophan are preferred.
[0020] In the present specification, the term "analogous compound" refers to a compound that has molecular biological properties such as receptor binding properties and structure similar to those of reduced glutathione, but has a composition in which an atom or atomic group constituting reduced glutathione is replaced with another atom or atomic group. Examples of the analogous compound include oxidized glutathione, NL-cysteinylglycine, and γ-glutamylcysteine, and among these, oxidized glutathione is preferred.
[0021] In this specification, "oxidized glutathione" refers to a molecule in which two molecules of reduced glutathione are linked by a disulfide bond. Hereinafter, oxidized glutathione may be abbreviated as "GSSG."
[0022] As used herein, the term "dipeptide" refers to a molecule in which two amino acids are linked by a peptide bond. Examples of dipeptides include L-alanine-L-glutamine and L-alanyl-L-cysteine, with L-alanyl-L-cysteine being preferred.
[0023] In the present specification, the term "aqueous solution" refers to a solution containing only water as a solvent or a solution containing water as a main solvent. The aqueous solution may contain, in addition to water, a water-soluble organic solvent such as methanol, ethanol, propanol, or acetone, as long as the effect of the present invention is not impaired.
[0024] In this specification, the term "aqueous solution of reduced glutathione" or "aqueous solution containing reduced glutathione" refers to an aqueous solution containing at least dissolved reduced glutathione, and may be a solution in which reduced glutathione is completely dissolved, or may contain α-type crystals of reduced glutathione in addition to dissolved reduced glutathione. (Method for storing the aqueous reduced glutathione solution of the present invention)
[0025] The present invention relates to a method for preserving an aqueous solution of reduced glutathione (hereinafter referred to as the "method for preserving an aqueous solution of the present invention"), which is characterized by causing one or more of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds, and dipeptides to coexist as a crystal habit modifier in order to suppress the generation of β-type crystals, which are stable crystals that have low solubility and easily precipitate in an aqueous solution of reduced glutathione. As the crystal habit modifier, the above-mentioned ones can be suitably used.
[0026] The aqueous solution of reduced glutathione (containing it) may contain at least one solute other than the crystal habit modifier selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds, and dipeptides, so long as it does not impair the effects of the present invention. Examples of such solutes include salts and buffers. Furthermore, the aqueous solution of reduced glutathione (containing it) may be the supernatant of a fermentation liquid containing reduced glutathione, a reaction liquid for producing reduced glutathione, etc. Examples of the salt include sodium chloride, sodium sulfate, etc., and examples of the buffer include sodium acetate, sodium bicarbonate, etc. There is no particular limitation on the method of making the crystal habit modifier coexist, and the crystal habit modifier may be added to the aqueous solution of reduced glutathione, or the aqueous solution of reduced glutathione may be added to the aqueous solution of reduced glutathione. When a solid crystal habit modifier is added, it is preferable to dissolve it after adding it to the aqueous solution of reduced glutathione. In addition, in the process of producing reduced glutathione by fermentation, extraction, or chemical synthesis, the crystal habit modifier of the present invention can be present in any step as long as the production of reduced glutathione is not hindered. Furthermore, by using a raw material containing the crystal habit modifier of the present invention, the crystal habit modifier of the present invention can be present in the reduced glutathione produced from the raw material.
[0027] In the method for preserving an aqueous solution of the present invention, the generation of β-type crystals and / or the transition from α-type crystals to β-type crystals can be suppressed for a longer period of time in the presence of a crystal habit modifier compared to the absence of such a modifier.
[0028] In the method for preserving an aqueous solution of the present invention, the temperature of the aqueous reduced glutathione solution is not particularly limited as long as the generation of β-type crystals and / or the transition from α-type crystals to β-type crystals does not occur, but a lower temperature is preferable in terms of suppressing the transition. The temperature of the aqueous reduced glutathione solution at which the generation of β-type crystals and / or the transition to β-type crystals does not occur varies depending on the type or concentration of the crystal habit modifier, but is usually 60° C. or lower, preferably 40° C. or lower, more preferably 25° C. or lower, and particularly preferably 10° C. or lower.
[0029] The amount of the crystal habit modifier added to the aqueous reduced glutathione solution is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, and particularly preferably 1% by weight or more, based on the amount of reduced glutathione. Also, it is desirable for the amount to be 10% by weight or less.
[0030] By adding a crystal habit modifier, the generation of β-type crystals is suppressed and a clear aqueous solution can be maintained even if the reduced glutathione concentration in the reduced glutathione aqueous solution is 30 g / L or more, which is the saturated solubility of β-type crystals at 10° C. Furthermore, when the reduced glutathione aqueous solution contains α-type crystals, the generation of β-type crystals and the transition to β-type crystals can be prevented even if the reduced glutathione concentration in the system is 30 g / L or more.
[0031] A suitable amount of crystal habit modifier can be determined, for example, as follows. The crystal habit modifier is added to an aqueous solution of reduced glutathione so that the concentration is about 5% by weight or less, and the solution is stirred for a certain period of time. The crystals precipitated during stirring are observed under a microscope to determine whether all the crystals are α-type crystals, or whether β-type crystals have developed or transitioned to β-type crystals has occurred. Since the shapes of α-type crystals, which are large columnar crystals, and β-type crystals, which are small needle-like crystals, are significantly different, the two can be easily distinguished by observation under a microscope. In order to quantitatively grasp the state of contamination of β-type crystals, the crystals obtained by separating a portion are dissolved in water at 25°C to a concentration of 100 g / L. After stirring and holding for a sufficient period of time, the solution is tested by a visible absorbance measurement method using a cell with a layer length of 1 cm, with water as a control, and the transmittance at 430 nm is measured to confirm turbidity. The transmittance can be expressed as transmittance (T%) 430 nm = 100 x 10-A (A = Abs: 430 nm, 1 cm). When β-type crystals with low solubility are present, the remaining crystals are detected as turbidity, and the transmittance of the solution is reduced. In addition, the generation of β-type crystals causes the reduced glutathione concentration of the solution in the crystallization or slurry to be lower than that of the solution containing only α-type crystals, so the type of coexisting crystals can also be identified by measuring the reduced glutathione concentration in the mother liquor from which the coexisting crystals have been removed. The reduced glutathione concentration in the mother liquor is measured using the following HPLC conditions after removing the coexisting crystals by filtration or the like, diluting with the mobile phase to a certain concentration, and stirring and holding for a sufficient time.
[0032] HPLC conditions Column: Inertsil ODS-3, inner diameter 3.0 mm, length 150 mm Column temperature: 35℃ Detector: UV detector Wavelength 210nm Mobile phase composition: Sodium 1-heptanesulfonate / potassium dihydrogen phosphate / phosphoric acid / methanol
[0033] The type and content of each crystal habit modifier component contained in the reduced glutathione aqueous solution can be measured, for example, by precisely weighing out about 0.25 g of the sample, dissolving it in pure water, making the volume 25 mL, and taking 1 mL of the solution. After adding a dilution buffer solution and making the volume 10 mL, the solution is centrifuged at 10,000 rpm for 5 minutes, and the supernatant is introduced into an amino acid analyzer JLC-500V (manufactured by JEOL Ltd.) and measured according to the instructions in the manual. (α-Crystals of Reduced Glutathione of the Present Invention)
[0034] The present invention relates to an α-type crystal of reduced glutathione containing the above-mentioned crystal habit modifier (hereinafter also referred to as "the α-type crystal of the present invention").
[0035] The α-type crystals of reduced glutathione are crystals having peaks at diffraction angles 2θ of 6.3°, 12.6°, 13.8°, 16.2°, 22.3°, 25.7°, 30.1°, 31.9°, 32.0°, and 33.5° in powder X-ray diffraction.
[0036] The content of the crystal habit modifier in the α-crystals of reduced glutathione is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, and particularly preferably 1.0% by weight or more, based on the α-crystals of reduced glutathione. Also, it is desirable that the content is 10% by weight or less.
[0037] By containing the above-mentioned crystal habit modifier, the α-type crystal of the present invention is inhibited from transforming into β-type crystal, which has low solubility and is difficult to process as a raw material.
[0038] The amount of crystal habit modifier contained in the α-type crystals of the present invention can be determined by diluting the α-type crystals of the present invention with a mobile phase to a certain concentration, stirring and maintaining the mixture for a sufficient period of time, and then measuring the concentration using the following HPLC conditions.
[0039] HPLC conditions Column: YMC Triart C18, inner diameter 3.0 mm, length 150 mm Column temperature: 40℃ Detector: Fluorescence detector Excitation wavelength 360nm / Fluorescence wavelength 440nm Mobile phase composition: trisodium citrate dihydrate / anhydrous sodium sulfate / n-propanol / sodium lauryl sulfate
[0040] The type and content of each crystal habit modifier component contained in the α-type crystal of the present invention can be measured, for example, by precisely weighing out about 0.25 g of a sample, dissolving it in pure water, adjusting the volume to 25 mL, and taking 1 mL of the sample. After adding a dilution buffer solution to adjust the volume to 10 mL, the solution is centrifuged at 10,000 rpm for 5 minutes, and the supernatant is introduced into an amino acid analyzer JLC-500V (manufactured by JEOL Ltd.) and measured according to the instructions. (Method for Preserving α-Type Crystals of Reduced Glutathione of the Present Invention)
[0041] The present invention relates to a method for preserving α-type crystals of reduced glutathione, characterized in that one or more types selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds, and dipeptides are allowed to coexist as a crystal habit modifier in order to suppress the transition of α-type crystals of reduced glutathione to β-type crystals, which have low solubility and are difficult to process as a raw material (hereinafter referred to as the "method for preserving α-type crystals of the present invention"). As the crystal habit modifier, the above-mentioned ones can be suitably used.
[0042] In addition, the α-type crystals of reduced glutathione may contain substances other than reduced glutathione and one or more substances selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds, and dipeptides, as long as the effects of the present invention are not impaired. Such substances may include, for example, salts, organic solvents and related compounds.
[0043] In the method for preserving α-type crystals of the present invention, in order to suppress the transition from α-type crystals to β-type crystals of reduced glutathione, a crystal habit modifier is made to coexist with the α-type crystals of reduced glutathione. There is no limitation on the method for making the α-type crystals of reduced glutathione coexist with the crystal habit modifier, but the crystals may be obtained by suspending the α-type crystals of reduced glutathione in a solution containing the crystal habit modifier and then separating the crystals, or by spraying a solution containing the crystal habit modifier onto the α-type crystals of reduced glutathione to obtain the crystals in the presence of the crystal habit modifier.
[0044] In the method for preserving α-type crystals of the present invention, the generation of β-type crystals and / or the transition from α-type crystals to β-type crystals can be suppressed for a longer period of time in the presence of a crystal habit modifier compared to the absence of such a modifier.
[0045] In the method for preserving α-type crystals of the present invention, the storage temperature of the α-type crystals of reduced glutathione is not particularly limited as long as the generation of β-type crystals and / or the transition from α-type crystals to β-type crystals does not occur, but a lower temperature is preferable in terms of suppressing the transition. The storage temperature of the α-type crystals of reduced glutathione at which the generation of β-type crystals and / or the transition to β-type crystals does not occur varies depending on the type or concentration of the crystal habit modifier, but specifically, it is usually 60° C. or lower, preferably 40° C. or lower, more preferably 25° C. or lower, and particularly preferably 10° C. or lower.
[0046] The amount of the crystal habit modifier added to the α-crystals of reduced glutathione is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, and particularly preferably 1.0% by weight or more, based on the α-crystals of reduced glutathione. Also, it is desirable that the amount is 10% by weight or less.
[0047] The amount of crystal habit modifier coexisting with the α-type crystals of reduced glutathione can be determined by diluting the α-type crystals of reduced glutathione coexisting with the crystal habit modifier with the mobile phase to a certain concentration, stirring and maintaining the mixture for a sufficient period of time, and then measuring the concentration using the following HPLC conditions.
[0048] HPLC conditions Column: YMC Triart C18, inner diameter 3.0 mm, length 150 mm Column temperature: 40℃ Detector: Fluorescence detector Excitation wavelength 360nm / Fluorescence wavelength 440nm Mobile phase composition: trisodium citrate dihydrate / anhydrous sodium sulfate / n-propanol / sodium lauryl sulfate
[0049] The type and content of each crystal habit modifier component contained in the α-type crystals of reduced glutathione can be measured, for example, by precisely weighing out about 0.25 g of a sample, dissolving it in pure water, making the volume 25 mL, and taking 1 mL of the sample. After adding a dilution buffer solution and making the volume 10 mL, the solution is centrifuged at 10,000 rpm for 5 minutes, and the supernatant is introduced into an amino acid analyzer JLC-500V (manufactured by JEOL Ltd.) and measured according to the instructions in the manual. (Method of Producing α-Type Crystals of Reduced Glutathione of the Present Invention)
[0050] The present invention relates to a method for producing α-type crystals of reduced glutathione (hereinafter referred to as the "production method of the present invention"), which comprises crystallizing α-type crystals of reduced glutathione from an aqueous solution of reduced glutathione in the presence of at least one crystal habit modifier selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds, and dipeptides to obtain α-type crystals of reduced glutathione. As the crystal habit modifier, the above-mentioned ones can be suitably used.
[0051] In order to make the reduced glutathione coexist with the crystal habit modifier, the crystal habit modifier may be added to the reduced glutathione aqueous solution, or reduced glutathione may be added to the crystal habit modifier solution. The crystal habit modifier to be added may be a solid or a solution. When a solid crystal habit modifier is added, it is preferable to dissolve it after adding it to the reduced glutathione aqueous solution. Furthermore, in the process of producing reduced glutathione by fermentation, extraction, or chemical synthesis, the crystal habit modifier of the present invention can be made to coexist in any step as long as it does not interfere with the production of reduced glutathione. In addition, by using a raw material containing the crystal habit modifier of the present invention, the crystal habit modifier of the present invention can be made to coexist with reduced glutathione produced from the raw material.
[0052] In the production method of the present invention, the crystal habit modifier may be added to the aqueous reduced glutathione solution before crystallization, or may be added after α-type crystals of reduced glutathione have precipitated and before the transition to β-type crystals begins.
[0053] The crystallization method is not particularly limited, and may be concentration crystallization, which involves concentrating an aqueous solution of reduced glutathione to effect crystallization, cooling crystallization, which involves cooling an aqueous solution of reduced glutathione to effect crystallization, or poor solvent crystallization, which involves adding a poor solvent to an aqueous solution of reduced glutathione to effect crystallization, or a combination of these methods. Examples of poor solvents include alcohols having 1 to 6 carbon atoms, as well as acetone, methyl ethyl ketone, and diethyl ketone.
[0054] By concentrating or cooling the aqueous solution of reduced glutathione to increase the concentration of reduced glutathione to the saturated solubility or higher, or by adding a poor solvent to the aqueous solution of reduced glutathione to decrease the saturated solubility, reduced glutathione crystals are crystallized. In this case, by making at least one crystal habit modifier selected from the group consisting of aliphatic amino acids, sulfur-containing amino acids, aromatic amino acids, related compounds, and dipeptides coexist, the generation of β-type crystals and the transition to β-type crystals after precipitation of α-type crystals can be suppressed for a longer period of time compared to the case in which the crystals are not coexisted, and thus α-type crystals can be efficiently and stably obtained.
[0055] In another embodiment, α-type crystals of reduced glutathione may be added as seed crystals prior to or during the concentrating, cooling or adding of a poor solvent to the aqueous reduced glutathione solution. The α-type crystals of reduced glutathione can be obtained, for example, by crystallizing the aqueous reduced glutathione solution at 25° C. or lower.
[0056] When crystallizing reduced glutathione from an aqueous solution of reduced glutathione, in the absence of a crystal habit modifier, the generation of β-type crystals of reduced glutathione or the transition from α-type crystals to β-type crystals easily occurs. This phenomenon is more prominent as the temperature increases. In contrast, in the presence of a crystal habit modifier, the temperature at which the transition of reduced glutathione to β-type crystals occurs can be made higher than in the absence of a crystal habit modifier. In addition, even at the same temperature, the time until the transition of reduced glutathione from α-type crystals to β-type crystals occurs can be extended.
[0057] In one embodiment of the production method of the present invention, the aqueous solution of reduced glutathione is concentrated to precipitate a part of reduced glutathione as α-type crystals, and the resulting slurry is cooled to further precipitate the dissolved reduced glutathione as α-type crystals. In this case, it is desirable to add a crystal habit modifier before or after concentrating the aqueous solution of reduced glutathione, or at least before the crystals of reduced glutathione are crystallized.
[0058] In the production method of the present invention, the temperature at which the α-type crystals of reduced glutathione are crystallized is not particularly limited as long as the generation of β-type crystals and / or the transition from α-type crystals to β-type crystals do not occur, but a lower temperature is preferable in terms of yield. The temperature at which the α-type crystals of reduced glutathione are crystallized, at which the generation of β-type crystals and / or the transition from α-type crystals to β-type crystals do not occur, varies depending on the type or concentration of the crystal habit modifier and is therefore desirably set appropriately, but is preferably 40° C. or lower, more preferably 25° C. or lower, and particularly preferably 10° C. or lower.
[0059] The concentration of the crystal habit modifier to be present in the reduced glutathione aqueous solution is, for example, preferably 0.01% by weight or more, more preferably 0.1% by weight or more, and particularly preferably 1.0% by weight or more, based on the reduced glutathione, when the crystallization temperature is 25° C. and the crystallization time is 24 hours or more. It is also preferably 10% by weight or less. However, the inhibitory effect of the crystal habit modifier on the generation of β-type crystals and the transition to β-type crystals may vary depending on the type of crystal habit modifier, the temperature at which crystallization is performed, and the type and concentration of components other than reduced glutathione and the crystal habit modifier contained in the reduced glutathione aqueous solution. Therefore, it is desirable to appropriately set the amount of the crystal habit modifier to be added depending on the reduced glutathione aqueous solution to which the present invention is applied, the type and concentration of the crystal habit modifier used, and the crystallization temperature. In order to extend the time for the generation of β-type crystals or the transition from α-type crystals to β-type crystals to occur, it is preferable to increase the concentration of the crystal habit modifier.
[0060] After the α-type crystals of reduced glutathione are precipitated as described above, the crystals are separated from the mother liquor to obtain the α-type crystals of reduced glutathione. Excessive habit modifier and impurities can be removed from the α-type crystals by recrystallization or crystal washing, etc. The obtained α-type crystals are desirably dried to prevent further transition to β-type crystals.
[0061] There is no limitation on the drying method, and for example, reduced pressure drying or ventilation drying can be used. The drying temperature may be any temperature at which reduced glutathione does not decompose, and is preferably 100° C. or lower, more preferably 60° C. or lower, and particularly preferably 25° C. or lower. The dried α-type crystals of reduced glutathione can be appropriately packaged to form a final product. EXAMPLES
[0062] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these descriptions.
[0063] Example 1 A confirmation test of the effect of adding a crystal habit modifier on the suppression of the transition of reduced glutathione α-type crystals to β-type crystals during storage
[0064] The α-type crystals of reduced glutathione (9 g) and water (30 mL) were mixed in a glass bottle. 0.45 g of each of L-alanine (hereinafter sometimes abbreviated as L-Ala), L-cysteine (hereinafter sometimes abbreviated as L-Cys), L-phenylalanine (hereinafter sometimes abbreviated as L-Phe), L-tryptophan (hereinafter sometimes abbreviated as L-Trp), D-proline (hereinafter sometimes abbreviated as D-Pro), L-alanyl-L-cysteine (hereinafter sometimes abbreviated as AlaCys) or oxidized glutathione (GSSG) was added to the preparation solution and dissolved. The glass bottle was shaken for 24 hours in a box dryer set at 25°C. After 24 hours, the crystals in the slurry were observed under a microscope to determine whether or not they had transitioned to β-type crystals.
[0065] As a result, inhibition of the transition from α-type crystals to β-type crystals was observed in the presence of any of the following compounds: L-alanine, L-cysteine, L-phenylalanine, L-tryptophan, D-proline, L-alanyl-L-cysteine, and oxidized glutathione.
[0066] Example 2 A confirmation test for the effect of adding a crystal habit modifier on the suppression of the formation of β-type crystals during storage of reduced glutathione α-type crystals
[0067] 5 g of α-type crystals of reduced glutathione were immersed in an aqueous solution (10 mL) containing 5% by weight (relative to reduced glutathione) of L-alanine, L-cysteine, L-phenylalanine, L-tryptophan, L-alanyl-L-cysteine or oxidized glutathione (GSSG) and L-histidine hydrochloride (hereinafter sometimes abbreviated as L-His) for a comparative test, and then the entire amount of crystals obtained when separated with a membrane filter was bottled and stored in a thermostatic bath so that the crystal part was at 40°C. After 3 hours, 1 g of each crystal was dissolved in 10 mL of water at 25°C, the transmittance at 430 nm was measured, and turbidity was confirmed to determine whether or not the transition to β-type crystals occurred. The results are shown in Table 1. In the crystal habit effect in Table 1, ○ indicates that the generation of β-type crystals was suppressed, and × indicates that β-type crystals were generated.
[0068] [Table 1]
[0069] As shown in Table 1, the formation of β-type crystals was suppressed by coexisting α-type crystals of reduced glutathione with L-alanine, L-cysteine, L-phenylalanine, L-tryptophan, L-alanyl-L-cysteine, or oxidized glutathione (GSSG).
[0070] Example 3 Confirmation test of the effect of adding a crystal habit modifier during storage of reduced glutathione aqueous solution
[0071] Reduced glutathione (100g) was weighed into a 1L beaker, water was added, and the mixture was diluted to 1L. The mixture was heated to 40°C to completely dissolve the crystals, and filtered using a membrane filter. The compound confirmed to have a habit modifier effect in [Example 1] and L-histidine hydrochloride for a comparative test were added at 5% by weight (relative to reduced glutathione) to the prepared reduced glutathione aqueous solution (100g / L), cooled to 10°C, and stirred for 24 hours. After 24 hours, the supernatant was filtered through a filter with a pore size of 0.45μm, and the concentration of reduced glutathione in the supernatant was measured by HPLC, and the presence or absence of β-type crystals was determined based on the change in concentration. The results are shown in Table 2. In the habit modifier effect in Table 2, ○ indicates that the generation of β-type crystals was suppressed, and × indicates that β-type crystals were generated.
[0072] [Table 2]
[0073] In the aqueous solutions of L-alanine, L-cysteine, L-phenylalanine, L-tryptophan, D-proline, L-alanyl-L-cysteine, or reduced glutathione containing oxidized glutathione (GSSG), the generation of β-type crystals was suppressed.
[0074] Example 4 A study on the amount of crystal habit modifier required to prevent the formation of β-type crystals during storage of reduced glutathione aqueous solution
[0075] Reduced glutathione (100g) was weighed into a 1L beaker, water was added, and the mixture was diluted to 1L. The mixture was heated to 40°C to completely dissolve the crystals, and then filtered using a membrane filter. L-alanine, which has been confirmed to have a habit modifier effect, was added in increments of 0.01% by weight to 1% by weight (relative to reduced glutathione) to the prepared reduced glutathione aqueous solution (100g / L), cooled to 10°C, and stirred for 15 hours. After 15 hours, the supernatant was filtered through a filter with a pore size of 0.45μm, and the concentration of reduced glutathione in the supernatant was measured by HPLC, and the presence or absence or degree of generation of β-type crystals was determined by observing the change in the concentration of reduced glutathione. The results of the change in reduced glutathione concentration over time and with or without a habit modifier are shown in Table 3.
[0076] [Table 3]
[0077] It was found that after 15 hours, about 20% of the reduced glutathione had formed as β-type crystals in an aqueous solution of reduced glutathione without the addition of L-alanine. On the other hand, it was found that the formation of β-type crystals was suppressed in an aqueous solution containing L-alanine as a crystal habit modifier. It was also found that the more L-alanine was added, the less likely it was that β-type crystals would form.
[0078] It was found that the amount of crystal habit modifier to be added to an aqueous solution of reduced glutathione is preferably 0.01% by weight or more, more preferably 0.1% by weight or more, and particularly preferably 1% by weight or more, in the case of L-alanine, relative to the reduced glutathione.
[0079] Example 5 Method for producing α-type crystals of reduced glutathione (1)
[0080] Reduced glutathione (50 g) and water (500 mL) were added to a 1 L beaker. 2.5 g each of L-alanine, L-cysteine, or oxidized glutathione was added to the preparation solution, which was heated to 40°C to completely dissolve the crystals, and filtered using a membrane filter. The preparation solution (filtrate) was concentrated using an evaporator so that the reduced glutathione concentration was equal to or higher than the saturated solubility of α-type crystals, and concentrated and crystallized reduced glutathione was performed. The concentrated solution was cooled to 25°C and stirred for 24 hours, after which the crystals in the slurry were observed under a microscope to determine whether or not they had transitioned to β-type crystals.
[0081] As a result, in the crystallization with the addition of L-alanine, L-cysteine or oxidized glutathione, only α-crystals were formed, without the generation of β-crystals.
[0082] Example 6 Method for producing α-type crystals of reduced glutathione (2)
[0083] Reduced glutathione (50 g) and water (500 mL) were added to a 1 L beaker. L-alanine or L-cysteine was added to the preparation solution at 10% by weight relative to reduced glutathione, and the solution was heated to 40°C to completely dissolve the crystals, followed by filtration using a membrane filter. The preparation solution (filtrate) was concentrated using an evaporator so that the reduced glutathione concentration was equal to or greater than the saturated solubility of α-type crystals, and concentrated and crystallized reduced glutathione was performed. The concentrated solution was cooled to 25°C and stirred for 24 hours, after which the crystals in the slurry were observed under a microscope to determine whether or not they had transitioned to β-type crystals.
[0084] As a result, in the crystallization with the addition of L-alanine or L-cysteine, only α-type crystals were crystallized, without the generation of β-type crystals. The crystals obtained by crystallization with the addition of 10% by weight of L-alanine or L-cysteine were found to be α-type crystals of reduced glutathione, with peaks at diffraction angles 2θ of 6.3°, 12.6°, 13.8°, 16.2°, 22.3°, 25.7°, 30.1°, 31.9°, 32.0° and 33.5° in powder X-ray diffraction. [Industrial Applicability]
[0085] According to the present invention, the occurrence of β-type crystals and the transition to β-type crystals are significantly suppressed by making a specific crystal habit modifier or preservative coexist during the production (crystallization) and storage of α-type crystals of reduced glutathione, and α-type crystals of reduced glutathione can be produced efficiently and stably. Furthermore, according to the present invention, α-type crystals of reduced glutathione excellent in both quality and productivity can be stably supplied, and therefore the present invention is useful in a wide range of fields such as pharmaceuticals, foods, and cosmetics.
[0086] This application is based on patent application No. 2015-114855 filed in Japan, the contents of which are incorporated in their entirety herein.
Claims
[Claim 1] A crystal habit modifier for suppressing the generation of β-type crystals of reduced glutathione and / or the transition from α-type crystals to β-type crystals of reduced glutathione, comprising at least one compound selected from the group consisting of L-alanine, D-proline, L-phenylalanine, L-tryptophan, oxidized glutathione, and L-alanyl-L-cysteine as an active ingredient.
Citation Information
Patent Citations
Method of purifying gluthathione and gamma-glutamylcysteine
JP1986282397A
Stabilization of reduced glutathione and stabilized composition
JP1993339286A
Method for crystallizing citrulline
JP2010059125A
Method for producing peptide
JP2011223896A
